FDA Approves Label Update for Twirla Contraceptive Patch, Effective September 2024
The U.S. Food and Drug Administration (FDA) has approved an updated label for Twirla, a weekly contraceptive patch, according to Exeltis USA, the manufacturer. The change aims to more accurately reflect the levels of levonorgestrel and ethinyl estradiol delivered to users, as stated in a press release issued on June 12, 2024.
What Changed on Twirla’s Label?
The updated label adjusts the documented daily release of hormones in Twirla from 120 µg of levonorgestrel and 30 µg of ethinyl estradiol to 115 µg of levonorgestrel and 28 µg of ethinyl estradiol. This revision aligns with findings from Study ATI-CL28, which evaluated hormone transfer rates, and follows FDA draft guidance for transdermal delivery systems. Exeltis USA emphasized that the formulation, composition, and manufacturing process remain unchanged.
When Will the Updated Label Be Available?
The revised labeling is expected to appear on Twirla products in September or October 2024. Until existing stock is depleted, patients may receive patches labeled with either the previous or updated strength. The company clarified that the dose and clinical effects of Twirla remain consistent regardless of the label version.
Why This Update Matters for Users
The adjustment addresses discrepancies between labeled and actual hormone delivery, which could impact contraceptive efficacy. Clinical guidelines note that Twirla is intended for women with a body mass index (BMI) below 30 kg/m². It is contraindicated for those with a BMI over 30 due to increased risks of side effects like blood clots, as well as reduced effectiveness in individuals with a BMI under 25 kg/m².
What Does This Mean for Contraceptive Safety?
The FDA’s approval underscores the agency’s focus on transparency in drug labeling. While the hormonal dose change is minimal, it highlights the importance of accurate dosing in transdermal systems, where absorption can vary based on skin properties and body weight. Health experts recommend that patients consult their healthcare providers to understand how this update may affect their individual treatment plans.